Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Ovarian Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Ovarian Serous Adenocarcinoma (31
)
Ovarian Serous Adenocarcinoma (31
)
›
Associations
(527)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
FOLR1 positive
Ovarian Cancer
FOLR1 positive
Ovarian Cancer
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
Immunogen Press Release - 5 days (New B)
mirvetuximab soravtansine-gynx
Sensitive
:
A1
Immunogen Press Release - 5d
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
Immunogen Press Release - 5 days
mirvetuximab soravtansine-gynx
Sensitive
:
A1
Immunogen Press Release - 5 days - (New B)
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
IDE161
Sensitive: B - Late Trials
IDEAYA Biosciences Press Release - 1 week (New B)
IDE161
Sensitive
:
B
IDEAYA Biosciences Press Release - 1wk
IDE161
Sensitive: B - Late Trials
IDEAYA Biosciences Press Release - 1 week
IDE161
Sensitive
:
B
IDEAYA Biosciences Press Release - 1 week - (New B)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
IDE161
Sensitive: B - Late Trials
IDEAYA Biosciences Press Release - 1 week (New B)
IDE161
Sensitive
:
B
IDEAYA Biosciences Press Release - 1wk
IDE161
Sensitive: B - Late Trials
IDEAYA Biosciences Press Release - 1 week
IDE161
Sensitive
:
B
IDEAYA Biosciences Press Release - 1 week - (New B)
FOLR1 overexpression
Ovarian Cancer
FOLR1 overexpression
Ovarian Cancer
mirvetuximab soravtansine-gynx
Sensitive: B - Late Trials
ESGO 2023 - 2 weeks (New B)
mirvetuximab soravtansine-gynx
Sensitive
:
B
ESGO 2023 - 2wk
mirvetuximab soravtansine-gynx
Sensitive: B - Late Trials
ESGO 2023 - 2 weeks
mirvetuximab soravtansine-gynx
Sensitive
:
B
ESGO 2023 - 2 weeks - (New B)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
ESGO 2023 - 2 weeks (New C3)
olaparib
Sensitive
:
A1
ESGO 2023 - 2wk
olaparib
Sensitive: A1 - Approval
ESGO 2023 - 2 weeks
olaparib
Sensitive
:
A1
ESGO 2023 - 2 weeks - (New C3)
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
ESGO 2023 - 2 weeks (New C3)
olaparib
Sensitive
:
A1
ESGO 2023 - 2wk
olaparib
Sensitive: A1 - Approval
ESGO 2023 - 2 weeks
olaparib
Sensitive
:
A1
ESGO 2023 - 2 weeks - (New C3)
PD-L1 expression
Ovarian Cancer
PD-L1 expression
Ovarian Cancer
pembrolizumab
Sensitive: C1 - Off-label
ESGO 2023 - 2 weeks (New C4)
pembrolizumab
Sensitive
:
C1
ESGO 2023 - 2wk
pembrolizumab
Sensitive: C1 - Off-label
ESGO 2023 - 2 weeks
pembrolizumab
Sensitive
:
C1
ESGO 2023 - 2 weeks - (New C4)
ER positive
Ovarian Cancer
ER positive
Ovarian Cancer
CDK4 inhibitor + CDK6 inhibitor
Sensitive: C3 – Early Trials
ESGO 2023 - 2 weeks (New C3)
CDK4 inhibitor + CDK6 inhibitor
Sensitive
:
C3
ESGO 2023 - 2wk
CDK4 inhibitor + CDK6 inhibitor
Sensitive: C3 – Early Trials
ESGO 2023 - 2 weeks
CDK4 inhibitor + CDK6 inhibitor
Sensitive
:
C3
ESGO 2023 - 2 weeks - (New C3)
LOX overexpression
Ovarian Cancer
LOX overexpression
Ovarian Cancer
cisplatin
Sensitive: D – Preclinical
ESGO 2023 - 2 weeks (New D)
cisplatin
Sensitive
:
D
ESGO 2023 - 2wk
cisplatin
Sensitive: D – Preclinical
ESGO 2023 - 2 weeks
cisplatin
Sensitive
:
D
ESGO 2023 - 2 weeks - (New D)
LOX overexpression
Ovarian Cancer
LOX overexpression
Ovarian Cancer
paclitaxel
Sensitive: D – Preclinical
ESGO 2023 - 2 weeks (New D)
paclitaxel
Sensitive
:
D
ESGO 2023 - 2wk
paclitaxel
Sensitive: D – Preclinical
ESGO 2023 - 2 weeks
paclitaxel
Sensitive
:
D
ESGO 2023 - 2 weeks - (New D)
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
C1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
C1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
C1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
C1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
C1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
C1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
topotecan
Sensitive: A1 - Approval
topotecan
Sensitive
:
A1
topotecan
Sensitive: A1 - Approval
topotecan
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
BRCA2 deletion
Ovarian Cancer
BRCA2 deletion
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA1 deletion
Ovarian Cancer
BRCA1 deletion
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
ifosfamide
Sensitive: A2 - Guideline
ifosfamide
Sensitive
:
A2
ifosfamide
Sensitive: A2 - Guideline
ifosfamide
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
leucovorin calcium
Sensitive: A2 - Guideline
leucovorin calcium
Sensitive
:
A2
leucovorin calcium
Sensitive: A2 - Guideline
leucovorin calcium
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login